Frank H. Neumann
Homburg, SL, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomas.
Journal: British journal of haematology
Published: February 18, 2026
Fura-10, unlike fura-2, is suitable for long-term calcium imaging in natural killer (NK) cells without compromising cytotoxicity and can be combined with target cell death analysis.
Journal: Cell calcium
Published: October 02, 2025
Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 28, 2025
Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms.
Journal: Nature communications
Published: March 13, 2025
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.
Journal: Nature cancer
Published: December 23, 2024
Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.
Journal: International journal of molecular sciences
Published: October 19, 2024
Multiplexed Immunophenotyping of Lymphoma Tissue Samples.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: October 18, 2024
Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.
Journal: Annals of hematology
Published: September 24, 2024
Last Updated: 09/26/2026